Ozempic Gastroparesis Lawsuits in 2026: What Patients Should Know

When Ozempic became a household name, millions of patients were told the main side effects to watch for were nausea, vomiting, and temporary digestive upset during dose escalation. What they were not adequately warned about, according to thousands of lawsuits now consolidated in federal court, was the risk of developing gastroparesis — a serious, sometimes permanent condition in which the stomach loses its ability to empty properly. As of early 2026, over 4,400 plaintiffs have joined litigation against Novo Nordisk (maker of Ozempic and Wegovy) and Eli Lilly (maker of Mounjaro and Zepbound), alleging inadequate warnings about GI-related risks. Here's what patients need to understand.

What the Ozempic Gastroparesis Lawsuits Allege

The lawsuits, which were consolidated into multidistrict litigation (MDL) in the Eastern District of Pennsylvania in 2023, center on several core allegations: **Failure to warn**: Plaintiffs allege that Novo Nordisk and Eli Lilly knew or should have known about the risk of serious, persistent gastroparesis but did not adequately disclose this risk on product labeling or to prescribing physicians. The FDA's adverse event reporting system (FAERS) had accumulated thousands of reports linking GLP-1 medications to gastroparesis and intestinal ileus (intestinal paralysis) before many patients were ever prescribed these drugs. **Negligent misrepresentation**: The lawsuits allege that drug makers marketed these medications with claims about their GI safety that did not reflect the full risk profile known to the companies from clinical trial data. **Design defect claims**: Some plaintiffs have included claims that the medications' mechanism of action — slowing gastric emptying — inherently creates a design risk for gastroparesis development, particularly with long-term use, that was not adequately studied before approval. **Damages**: Plaintiffs are seeking compensation for medical expenses (often substantial, given the complexity of gastroparesis treatment), lost wages, pain and suffering, and in some cases permanent disability.

What Is Gastroparesis and How Serious Is It?

Gastroparesis literally means 'stomach paralysis' — though in practice it is more accurately described as significantly delayed gastric emptying without mechanical obstruction. Under normal circumstances, stomach muscles contract rhythmically to break down food and push it into the small intestine within 2-4 hours of eating. In gastroparesis, this process is severely impaired, causing food to remain in the stomach for far longer. Symptoms of gastroparesis include: - Nausea and vomiting, often of undigested food eaten many hours earlier - Feeling full after just a few bites of food (early satiety) - Upper abdominal pain, bloating, and distension - Loss of appetite and unintentional weight loss - Fluctuating blood sugar levels (particularly concerning in diabetic patients) - Malnutrition and nutrient deficiencies from impaired absorption Gastroparesis ranges from mild (manageable with dietary modification) to severe (requiring nasogastric tube feeding or parenteral nutrition). In its severe forms, it is genuinely disabling and significantly reduces quality of life. While some drug-induced gastroparesis resolves after discontinuing the offending medication, others develop persistent or permanent motility dysfunction. The condition is not rare in the general population — it's estimated to affect 5 million Americans, primarily women and people with diabetes. But the lawsuits allege a meaningful additional population has developed it specifically as a consequence of GLP-1 drug use without adequate forewarning.

How to Know If You May Be Affected

Not everyone who experiences GI symptoms on a GLP-1 medication has gastroparesis. The normal, expected side effects of nausea and slowed digestion during dose escalation are different from the pathological condition of gastroparesis. The key distinctions: **Characteristics more consistent with drug-induced gastroparesis:** - Vomiting of food eaten 2, 4, or more hours prior (undigested food that should have left the stomach long ago) - Symptoms that do not improve with dose stabilization and persist for months - Inability to maintain adequate nutrition without extreme dietary modification - Significant unintentional weight loss beyond what would be expected from the medication's appetite effects - New or significantly worsening acid reflux (caused by food remaining in the stomach) - Blood sugar fluctuations that are harder to predict or control than before starting the medication (in diabetic patients) **Getting diagnosed:** The gold standard for gastroparesis diagnosis is a gastric emptying study (GES) — a nuclear medicine test where you eat radioactively labeled food and are scanned at intervals (1, 2, and 4 hours) to measure how quickly it leaves your stomach. Gastroparesis is defined as more than 10% of the test meal remaining in the stomach at 4 hours. If you suspect gastroparesis, request this test specifically — a normal endoscopy or ultrasound will not diagnose it, as it's a functional problem, not a structural one. **Documentation:** If you believe your symptoms may be medication-related, detailed documentation from the time your symptoms began is valuable both for medical management and for any potential legal process. Keep records of: - When you started the medication and at what dose - When GI symptoms began - All medical appointments and test results related to these symptoms - Work or daily life impacts of your symptoms

The Gastroparesis–SIBO Connection

One of the most important and underappreciated aspects of GLP-1-related GI dysfunction is the relationship between gastroparesis and small intestinal bacterial overgrowth (SIBO). These conditions frequently co-occur and can create a vicious cycle that makes both harder to treat. Here's the mechanism: the migrating motor complex (MMC) is a series of electrical and muscular waves that sweep the small intestine clean of bacteria and food debris approximately every 90-120 minutes during fasting. This 'housekeeping' mechanism is one of the primary defenses against SIBO. The MMC is initiated by signals from the stomach — when the stomach empties normally and the small intestine is fasting, the MMC activates. In gastroparesis, the stomach doesn't empty properly. This means food is continuously present in the stomach and upper GI tract, disrupting the normal fasting signal that triggers the MMC. Without regular MMC sweeping, bacteria that should remain in the colon begin to accumulate in the small intestine. This is SIBO. For patients with GLP-1-induced gastroparesis who then develop SIBO, the clinical picture becomes significantly more complex: - SIBO treatment (antimicrobials) addresses the bacterial component, but without treating the gastroparesis-driven motility impairment, SIBO rapidly recurs - Dietary modifications for gastroparesis (liquid, soft foods) often conflict with SIBO dietary recommendations - Standard prokinetics used for gastroparesis may help both conditions, but medication interactions need to be managed carefully If you have confirmed GLP-1-related gastroparesis, proactive SIBO testing is a reasonable step given this mechanistic link.

What to Do If You Think You Have Drug-Induced Gastroparesis

First, get medically evaluated. This is your most important step, both for your health and for any potential legal process. Request a gastroenterology referral and specifically ask about a gastric emptying study if your prescribing provider isn't already ordering one. Discuss medication management options with your providers. These may include dose reduction, switching to a different GLP-1 drug with a different pharmacokinetic profile, or discontinuing GLP-1 therapy entirely. The right answer depends on your metabolic situation, the severity of your GI symptoms, and what alternatives exist for managing your underlying condition. If you are managing diabetes and gastroparesis simultaneously, be aware that gastroparesis significantly complicates blood sugar control — food absorption becomes unpredictable, which makes insulin dosing more challenging. Work closely with your endocrinologist or diabetes care team during this period. For SIBO assessment: given the mechanical link described above, discuss SIBO breath testing with your GI specialist if you're experiencing the typical SIBO symptom cluster (bloating after meals, gas, altered bowel habits) alongside gastroparesis symptoms. Regarding the legal process: if you believe you have experienced significant harm from GLP-1-induced gastroparesis, consulting with an attorney specializing in pharmaceutical litigation is a separate and independent step from medical management. Many law firms offer free consultations. Statutes of limitations vary by state, so if this is something you're considering, don't delay indefinitely.

The Broader Lesson for GLP-1 Drug Monitoring

The Ozempic gastroparesis litigation represents a broader challenge in pharmaceutical development: when drugs are prescribed at massive scale, rare and serious adverse events that may not surface in pre-approval clinical trials become visible in the population. GLP-1 receptor agonists were approved based on clinical trials that were not powered to detect or characterize the risk of persistent gastroparesis, particularly with long-term use. This does not mean the drugs should not be used. For the tens of millions of people with type 2 diabetes and obesity, GLP-1 agonists represent transformative therapy with robust cardiovascular and metabolic benefits that save lives. The benefit-risk calculation for most patients remains clearly favorable. What it does mean is that post-market surveillance, informed consent, careful patient monitoring, and responsive medical management when GI symptoms persist are all essential — and that patients who develop serious GI complications deserve to have those complications taken seriously, properly diagnosed, and appropriately treated, regardless of what happens in the courts.

**Disclaimer:** This article is for informational and educational purposes only and does not constitute medical or legal advice. Always consult with a qualified healthcare provider regarding medical decisions and with a licensed attorney regarding legal matters. The litigation landscape around GLP-1 medications is rapidly evolving; information in this article reflects the state of public reporting as of April 2026.